Fujifilm Diosynth Biotechnologies says the site in Billingham will support biologic, vaccine and gene therapy development and manufacturing for its customers. Work began on the site in Billingham in the North of England this week, 10 months after the contract development and manufacturing organization (CDMO) first announced plans for the biocampus to support its pharma clients in the development and manufacture of biologics, vaccines and gene therapies. The expansion, set to represent an investment of up to $14.5 million (€13…